{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:45:31Z","timestamp":1789623931865,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["K99MD015767"],"award-info":[{"award-number":["K99MD015767"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaci.2022.11.021","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:48:25Z","timestamp":1671274105000},"page":"747-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A\u00a0Bayesian network meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0428-973X","authenticated-orcid":false,"given":"Tanawin","family":"Nopsopon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lassiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Keet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwanhee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-1470","authenticated-orcid":false,"given":"Ayobami","family":"Akenroye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.11.021_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1183\/09031936.04.00004904","article-title":"Asthma severity and medical resource utilisation","volume":"23","author":"Antonicelli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.11.021_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1398-9995.2006.01254.x","article-title":"Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma","volume":"62","author":"Sullivan","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.11.021_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/03007995.2018.1505352","article-title":"Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA steps 4 or 5 treatment","volume":"34","author":"Chen","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2022.11.021_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.11.021_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.11.021_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.11.021_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","article-title":"Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison","volume":"25","author":"Menzies-Gow","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jaci.2022.11.021_bib12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaci.2022.11.021_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jaci.2022.11.021_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaci.2022.11.021_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.11.021_bib19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.11.021_bib22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.11.021_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.11.021_bib27","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.11.021_bib28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib29","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.11.021_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","article-title":"Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses","volume":"69","author":"Nakajima","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2022.11.021_bib32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.4049\/jimmunol.178.3.1396","article-title":"Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin","volume":"178","author":"Omori","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.11.021_bib33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imr.12706","article-title":"The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms","volume":"286","author":"Kabata","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2022.11.021_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2022.11.021_bib36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nm734","article-title":"Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma","volume":"8","author":"Kuperman","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib37","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1172\/JCI36130","article-title":"The cytokine network in asthma and chronic obstructive pulmonary disease","volume":"118","author":"Barnes","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.11.021_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603312","article-title":"Molecular targets for biological therapies of severe asthma","volume":"11","author":"Pelaia","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.11.021_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u201cbomb\u201d (blood eosinophils) meets \u201cmagnet\u201d (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.jaci.2022.11.021_bib40","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.11.021_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00408-019-00310-8","article-title":"Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis","volume":"198","author":"Ramonell","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.jaci.2022.11.021_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/JAA.S275068","article-title":"Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function","volume":"13","author":"Pavord","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2022.11.021_bib43","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.11.021_bib44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02250-2018","article-title":"The interleukin-13 paradox in asthma: effective biology, ineffective biologicals","volume":"53","author":"Nair","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.11.021_bib45","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2022.11.021_bib46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jaip.2019.04.019","article-title":"Association between pulmonary function and asthma symptoms","volume":"7","author":"Sullivan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.11.021_bib47","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.clinthera.2008.10.005","article-title":"Validation of the Spanish version of the Asthma Control Questionnaire","volume":"30","author":"Picado","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2022.11.021_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir Res"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922024988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922024988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:40:18Z","timestamp":1758793218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922024988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0091674922024988"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.11.021","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A\u00a0Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}